CA2566716C - Prolongation of survival of an allograft by inhibiting complement activity - Google Patents

Prolongation of survival of an allograft by inhibiting complement activity Download PDF

Info

Publication number
CA2566716C
CA2566716C CA2566716A CA2566716A CA2566716C CA 2566716 C CA2566716 C CA 2566716C CA 2566716 A CA2566716 A CA 2566716A CA 2566716 A CA2566716 A CA 2566716A CA 2566716 C CA2566716 C CA 2566716C
Authority
CA
Canada
Prior art keywords
allograft
complement activity
methods
survival
prolongation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2566716A
Other languages
English (en)
French (fr)
Other versions
CA2566716A1 (en
Inventor
Russell P. Rother
Zhen Zhong
Hao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2566716(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CA2566716A1 publication Critical patent/CA2566716A1/en
Application granted granted Critical
Publication of CA2566716C publication Critical patent/CA2566716C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2566716A 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity Expired - Fee Related CA2566716C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57144404P 2004-05-14 2004-05-14
US60/571,444 2004-05-14
PCT/US2005/017048 WO2005110481A2 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Publications (2)

Publication Number Publication Date
CA2566716A1 CA2566716A1 (en) 2005-11-24
CA2566716C true CA2566716C (en) 2014-12-23

Family

ID=35385551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2566716A Expired - Fee Related CA2566716C (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Country Status (14)

Country Link
US (3) US20090028850A1 (enExample)
EP (4) EP3056218A1 (enExample)
JP (3) JP5161567B2 (enExample)
AU (1) AU2005244012C1 (enExample)
CA (1) CA2566716C (enExample)
DK (1) DK1755674T3 (enExample)
ES (1) ES2528362T3 (enExample)
HK (2) HK1222342A1 (enExample)
IL (2) IL179240A (enExample)
NZ (1) NZ551308A (enExample)
PL (1) PL1755674T3 (enExample)
PT (1) PT1755674E (enExample)
SI (1) SI1755674T1 (enExample)
WO (1) WO2005110481A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056218A1 (en) 2004-05-14 2016-08-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
EP1988882B1 (en) * 2006-03-02 2014-12-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
DK2359834T5 (en) * 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
RS64039B1 (sr) * 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
AU2010266127B2 (en) * 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
PL2884999T3 (pl) 2012-08-20 2021-07-05 Fred Hutchinson Cancer Research Center Sposób i kompozycje do immunoterapii komórkowej
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
EP3033093A1 (en) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
US20180311299A1 (en) * 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
MY191668A (en) 2016-06-14 2022-07-06 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
CN120344253A (zh) * 2022-12-08 2025-07-18 诺麦塔制药有限公司 延长移植物和受体存活期的组合物和方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
EP0560929A1 (en) 1990-12-06 1993-09-22 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
ATE265220T1 (de) 1998-02-04 2004-05-15 Gen Hospital Corp Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
US6302855B1 (en) * 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
AU2001296594A1 (en) * 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
PL364359A1 (en) * 2001-06-08 2004-12-13 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
EP1478354A4 (en) 2002-01-22 2008-09-24 Genzyme Corp USE OF TGF-BETA ANTAGONISTS IN THE TREATMENT OR PREVENTION OF CHRONIC RELEASE OF TRANSPLANT
US7923010B2 (en) * 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP3056218A1 (en) 2004-05-14 2016-08-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
CA2566861A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
DK1755674T3 (en) 2015-02-09
HK1201758A1 (en) 2015-09-11
PT1755674E (pt) 2015-02-05
EP2338511A3 (en) 2012-07-25
EP1755674A2 (en) 2007-02-28
EP1755674B1 (en) 2014-11-19
ES2528362T3 (es) 2015-02-09
JP2013032391A (ja) 2013-02-14
SI1755674T1 (sl) 2015-04-30
NZ551308A (en) 2009-06-26
WO2005110481A3 (en) 2006-06-22
JP2007537299A (ja) 2007-12-20
WO2005110481A2 (en) 2005-11-24
AU2005244012B9 (en) 2011-11-03
EP2338511A2 (en) 2011-06-29
JP2014080438A (ja) 2014-05-08
JP5590624B2 (ja) 2014-09-17
PL1755674T3 (pl) 2015-05-29
EP3056218A1 (en) 2016-08-17
AU2005244012A1 (en) 2005-11-24
US20190309053A1 (en) 2019-10-10
US20090028850A1 (en) 2009-01-29
IL179240A0 (en) 2007-03-08
EP2815767A1 (en) 2014-12-24
IL233326A0 (en) 2014-08-31
HK1101962A1 (en) 2007-11-02
JP5161567B2 (ja) 2013-03-13
US20170267751A1 (en) 2017-09-21
IL179240A (en) 2014-07-31
HK1222342A1 (en) 2017-06-30
AU2005244012C1 (en) 2013-05-02
AU2005244012B2 (en) 2011-08-18
CA2566716A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
SG171578A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
CA2566716C (en) Prolongation of survival of an allograft by inhibiting complement activity
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
NZ599825A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
TW200718689A (en) 2-Amino-quinazolin-5-ones
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
NO20092146L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
WO2019242983A3 (en) Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor
GEP20115230B (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
EP2633856A3 (en) ATP citrate lyase inhibitors for treating cancer
WO2007062413A3 (en) Use of parp-1 inhibitors
WO2007047194A3 (en) Methods for treating mitf-related disorders
MXPA05010388A (es) Dispositivos, metodos y composiciones para prevenir la restenosis.
WO2005081904A3 (en) Antimicrobial carbohydrates and methods of using same
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
EP4585223A3 (en) Transplanted cell protection via inhibition of polymorphonuclear cells
WO2006086498A3 (en) Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2008008549A3 (en) Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat neoplasia

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831